Why Do Cancer Patients Lose Motivation? Scientists Trace It to Brain Pathway

Fatigue and lack of motivation in late-stage cancer patients have long been attributed to physical decline and severe weight loss. However, new research from Washington University School of Medicine in St. Louis challenges this view, revealing that these symptoms are driven by specific inflammation-sensing neurons in the brain (1^✔ ✔Trusted Source
A neuroimmune circuit mediates cancer cachexia-associated apathy

Go to source). In a study published in Science, the researchers report that they identified a direct connection between cancer-related inflammation and the loss of motivation characteristic of advanced cancer. Studying mice with cancer-linked cachexia, a condition typical of the disease that leads to muscle wasting and weight loss, they discovered a previously unrecognized pathway in the brain. This pathway senses inflammation and actively suppresses dopamine — a key driver of motivation — resulting in apathy and loss of drive.

Blocking the pathway restored motivation, even though the cancer and weight loss continued. This indicates that apathy can be treated separately from the disease itself.

Link Between Inflammation and Cancer Apathy

“The implications of the research are profound,” said the study’s lead author, Adam Kepecs, PhD, professor of neuroscience and of psychiatry at WashU Medicine. “We’ve uncovered a direct brain mechanism through which inflammation drives apathy in cancer, and we were able to restore normal motivation in mice with cachexia, despite ongoing inflammation as cancer progressed.”

About 70% of patients with advanced cancer experience cachexia. In addition to physical decline, patients often suffer from severe fatigue, apathy and a lack of motivation that affect their overall quality of life.

To understand whether these psychological symptoms are side effects that emerge from physical deterioration or whether they arise from distinct biological mechanisms, the research team, including Marco Pignatelli, MD, an assistant professor of psychiatry at WashU Medicine, and Tobias Janowitz, MD, PhD, an associate professor at Cold Spring Harbor Laboratory, turned to a well-validated mouse model of cancer cachexia. They focused specifically on behavioral symptoms, which had not previously been investigated, and mapped the brain regions involved.

They discovered that a structure in the brainstem, a part of the brain that controls vital functions such as breathing and heart rate, acts as a sensor for inflammatory signals in the bloodstream, particularly a molecule called interleukin-6 (IL-6), which is elevated in cancer cachexia. When IL-6 levels rise, neurons in this region of the brainstem transmit a signal through a defined pathway that suppresses dopamine release in a part of the brain called the nucleus accumbens, which is key for motivation and reward. The resulting drop in dopamine had the effect of making the mice less motivated to exert themselves to complete activities.

To see if interfering with this response could treat the lack of motivation and apathy, Kepecs and his colleagues tried two different approaches: they boosted dopamine levels and blocked inflammation-sensing neurons in the brainstem. Both approaches eliminated or reduced apathy in the mice. Treating the mice with an IL-6 antibody similar to an existing FDA-approved drug for rheumatoid arthritis, an inflammatory condition, also restored the animal’s motivation, a finding that points to a potential treatment for the psychological symptoms associated with advanced cancer.

“What’s remarkable is that motivation was restored even in late-stage disease,” said Pignatelli. “It suggests we may be able to improve quality of life by targeting the brain circuit.”

For acute illnesses such as infections, this inflammation-driven reduction in motivation may be adaptive, helping the body conserve energy to fight off disease, Kepecs explained. But in chronic conditions such as cachexia, prolonged apathy — including a reduced drive to eat, move or engage socially – can become harmful, worsening health and quality of life. Because IL-6 — the inflammatory molecule driving this effect — is elevated in many other conditions, and the brain regions involved are central to motivation, this same circuit likely contributes to apathy across a range of chronic illnesses.

“This gives us a new way to understand apathy in advanced cancer,” said Kepecs. “It’s not just a byproduct of physical decline, but a direct response to inflammation in the brain. That means we can potentially target the underlying biology to improve motivation and quality of life — even when the cancer itself is no longer treatable.”

Reference:

1. A neuroimmune circuit mediates cancer cachexia-associated apathy - (https://www.science.org/doi/10.1126/science.adm8857)

Source-Eurekalert